# US 2019/0153472 A1 · Methods and compositions for performing continuous directed evolution

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0153472 A1
- Document ID: US20190153472A1
- Status: Published application
- Kind: A1
- Application number: 16/171,424
- Filed: 2018-10-26
- Published: 2019-05-23
- Earliest claimed: 2017-10-27
- Assignees: Massachusetts Institute of Technology
- Applicants: Massachusetts Institute of Technology
- Inventors: Matthew D. Shoulders; Chet Berman; Christopher Lawrence Moore; Louis John Papa; Samuel Joseph Hendel
- Web page: https://patentgrep.com/patent/US20190153472A1

## CPC

- C12N 15/86: Viral vectors
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12N 9/50: Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12N 15/66: General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C12N 15/861: Adenoviral vectors
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2710/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10321: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12Y 207/07007: DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- C12Y 304/21014: Microbial serine proteases (3.4.21.14) (C12Y304/21062 - C12Y304/21067 takes precedence)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are methods of performing continuous directed evolution in complex biological systems, including metazoan cells. These methods include the infection of engineered, non-naturally occurring metazoan cells with engineered, non-naturally occurring DNA viruses. The generation of infectious viruses that can infect new cells depends on the evolution of a gene of interest which is driven by an error-prone adenoviral polymerase. Also disclosed herein, are the compositions of engineered, non-naturally occurring metazoan cells and engineered, non-naturally occurring DNA viruses that function as components in the continuous directed evolution methodologies.

## Claims

### Claim 1

An engineered, non-naturally occurring DNA virus comprising a modified genome, wherein the modified genome comprises:
(a) an integration of at least one polynucleic acid sequence comprising the sequence of a transcribable gene of interest,
(b) a deletion of the sequence encoding for the viral DNA polymerase, and
(c) a deletion of at least one sequence encoding for a protein necessary for the production of infectious DNA virus particles, and
optionally wherein the at least one sequence encoding for a protein necessary for the production of infectious DNA virus particles is not the sequence of the adenoviral fiber protein.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The engineered, non-naturally occurring DNA virus of claim 1, wherein the DNA virus is an adenovirus, optionally wherein the adenovirus is:
(a) derived from an adenovirus selected from the genera consisting of Adenovirus, Aviadenovirus, Ichtadenovirus, Mastadenovirus, and Siadenovirus;
(b) a human adenovirus selected from the group consisting of HAdV-A, HAdV-B, HAdV-C, HAdV-D, HAdV-E, HAdV-F, and HAdV-G, optionally wherein the HAdV-C adenovirus is selected from the group consisting of HAd2 and HAd5.

### Claim at position 4

-7. (canceled)

### Claim 8 (depends on 1)

The engineered, non-naturally occurring adenovirus of claim 1, wherein the at least one sequence encoding for a protein necessary for the production of infectious DNA virus particles comprises the sequence encoding for the adenoviral protease.

### Claim 9

An engineered, non-naturally occurring living metazoan cell comprising a modified genome, wherein the modified genome comprises:
(a) an integration of a polynucleic acid sequence comprising the sequence of an error-prone DNA virus DNA polymerase, and
(b) an integration of at least one polynucleic acid sequence comprising a sequence encoding for an expressible protein, wherein said expressible protein is necessary for the production of infectious DNA virus particles; and
optionally wherein the sequence encoding for a protein necessary for the production of infectious DNA virus particles is not the sequence of the adenoviral fiber protein.

### Claim 10 (depends on 9)

The engineered, non-naturally occurring living metazoan cell of claim 9, wherein the sequence of the error-prone DNA virus DNA polymerase is the sequence of an error-prone adenoviral DNA polymerase.

### Claim at position 8

-12. (canceled)

### Claim 13 (depends on 9)

The engineered, non-naturally occurring living metazoan cell of claim 9, wherein the engineered, non-naturally occurring living metazoan cell is derived from the group consisting of a human, mouse, rat, cat, dog, pig, guinea pig, hamster, sheep, macaque, and chimpanzee cell, optionally wherein the human cell is a human cell line.

### Claim at position 10

-15. (canceled)

### Claim 16 (depends on 9)

The engineered, non-naturally occurring living metazoan cell of claim 9, wherein the sequence of the error-prone DNA virus DNA polymerase is a non-natural adenoviral polymerase sequence derived from a sequences selected from the group consisting of the HAd2 and HAd5 DNA polymerase sequence, optionally wherein the HAd5 DNA polymerase:
(a) comprises the HAd5 DNA polymerase sequence with at least one mutation selected from the group consisting of T286I, N417A, F421Y, S506T, V585A, and D827A; or
(b) consists of SEQ ID NO: 27.

### Claim at position 12

-19. (canceled)

### Claim 20 (depends on 9)

The engineered, non-naturally occurring living metazoan cell of claim 9, wherein one of the at least one polynucleic acid sequence comprising a sequence encoding for a protein necessary for the production of infectious DNA virus particles comprises the sequence of the adenoviral protease.

### Claim 21

A method of performing continuous directed evolution of a polynucleic acid sequence, wherein said polynucleic acid sequence comprises the sequence of at least one gene of interest, said method comprising infecting engineered, non-naturally occurring living metazoan cells with at least one engineered, non-naturally occurring DNA virus, wherein:
(a) the at least one engineered, non-naturally occurring DNA virus comprises a modified genome, wherein the modified genome comprises:
(i) an integration of at least one polynucleic acid sequence comprising the sequence of a transcribable gene of interest,
(ii) a deletion of the sequence encoding for the viral DNA polymerase,
(iii) a deletion of at least one sequence encoding for a protein necessary for the production of infectious DNA virus particles, and
optionally wherein the at least one sequence encoding for a protein necessary for the production of infectious DNA virus particles is not the sequence of the adenoviral fiber protein; and
(b) the engineered, non-naturally occurring living metazoan cells comprise modified genomes, wherein each modified genome comprises:
(i) an integration of a polynucleic acid sequence comprising the sequence of an error-prone DNA virus DNA polymerase, and
(ii) an integration of at least one polynucleic acid sequence comprising the sequence encoding for the protein necessary for the production of infectious DNA virus particles in (a)(iii) under the control of a functionally-coupled promoter, optionally a transcriptionally-coupled promoter, and
(c) generating infectious DNA virus particles by the engineered, non-naturally occurring living metazoan cells infected with the at least one engineered, non-naturally occurring DNA virus, wherein the generation of the infectious DNA virus particles is dependent upon the evolution of the at least one polynucleic acid sequence comprising the sequence of the transcribable gene of interest in (a)(i), wherein said evolution is driven by the error-prone DNA virus DNA polymerase encoded by the polynucleic acid sequence of (b)(i).

### Claim 22 (depends on 21)

The method of claim 21, further comprising screening the engineered, non-naturally occurring living metazoan cells for highly infectious DNA virus particles.

### Claim 23 (depends on 21)

The method of claim 21, wherein at least one of the at least one polynucleic acid sequences comprising the sequence of a transcribable gene of interest in (a)(i) is a protein coding sequence, wherein expression and translation of the protein coding sequence generates at least one protein product, optionally wherein the at least one protein product, when unevolved:
(a) induces the expression of the at least one polynucleic acid sequence comprising the sequence encoding for the protein necessary for the production of infectious DNA virus particles in (b)(ii), and administering an agent that decreases the capability of the at least one protein product of inducing expression of the protein necessary for the production of infectious DNA virus particles in (b)(ii);
(b) inhibits the expression of the at least one polynucleic acid sequence comprising the sequence encoding for the protein necessary for the production of infectious DNA virus particles in (b)(ii);
(c) cannot induce the expression of the at least one polynucleic acid sequence comprising the sequence encoding for the protein necessary for the production of infectious DNA virus particles in (b)(ii);
(d) regulates the stability of the protein necessary for the production of infectious DNA viruses; or
(e) regulates the subcellular trafficking of the protein necessary for the production of infectious DNA viruses.

### Claim at position 17

-28. (canceled)

### Claim 29 (depends on 21)

The method of claim 21, wherein the sequence encoding for the protein necessary for the production of infectious DNA virus particles in (b)(ii) further comprises the sequence of an inhibitory tag, wherein the sequence of the protein necessary for the production of infectious DNA virus particles and the sequence of the inhibitory tag are coupled, and wherein:
(a) translation of the sequence comprising the sequence encoding for the protein necessary for the production of infectious DNA virus particles and the sequence of the inhibitory tag generates a tagged protein; and
(b) removal of inhibitory tag in (a) is dependent upon the evolution of the at least one polynucleic acid sequence comprising the sequence of the gene of interest;
optionally wherein:
the inhibitory tag is selected from the group consisting of a protein degradation tag or a protein sequestration tag, optionally wherein the protein degradation tag is a degron tag; or
the gene of interest is a protease.

### Claim at position 19

-32. (canceled)

### Claim 33 (depends on 21)

The method of claim 21, wherein:
(a) at least one of the at least one polynucleic acid sequences comprising the sequence of a transcribable gene of interest in (a)(i) is the sequence of a non-coding RNA; and/or
(b) the sequence encoding for the protein necessary for the production of infectious DNA virus particles in (b)(ii) further comprises a premature stop codon in the sequence encoding for the at least one protein necessary for the production of infectious DNA virus particles.

### Claim 34

(canceled)

### Claim 35 (depends on 33)

The method of claim 33, wherein the sequence of the gene of interest comprises the sequence of a tRNA or an aminoacyl tRNA synthetase.

### Claim at position 23

-37. (canceled)

### Claim 38 (depends on 21)

The method of claim 21, wherein the at least one engineered, non-naturally occurring DNA virus is derived from an adenovirus, optionally wherein the adenovirus is:
(a) derived from an adenovirus selected from the genera consisting of Adenovirus, Aviadenovirus, Ichtadenovirus, Mastadenovirus, and Siadenovirus;
(b) a human adenovirus selected from the group consisting of HAdV-A, HAdV-B, HAdV-C, HAdV-D, HAdV-E, HAdV-F, and HAdV-G, optionally wherein the HAdV-C adenovirus is selected from the group consisting of HAd2 and HAd5.

### Claim at position 25

-42. (canceled)

### Claim 43 (depends on 2)

The method of claim 2, wherein one of the at least one sequence encoding for a protein necessary for the production of infectious DNA viral particles comprises the sequence encoding for the adenoviral protease.

### Claim 44 (depends on 21)

The method of claim 21, wherein the engineered, non-naturally occurring living metazoan cells are derived from the group consisting of a human, mouse, rat, cat, dog, pig, guinea pig, hamster, sheep, macaque, and chimpanzee cells, optionally wherein the human cell is a human cell line.

### Claim at position 28

-46. (canceled)

### Claim 47 (depends on 21)

The method of claim 21, wherein the sequence of the error-prone DNA virus DNA polymerase is a non-natural adenoviral polymerase sequence derived from a sequences selected from the group consisting of the HAd2 and HAd5 DNA polymerase sequence, optionally wherein the HAd5 DNA polymerase:
(a) comprises the HAd5 DNA polymerase sequence with at least one mutation selected from the group consisting of T286I, N417A, F421Y, S506T, V585A, and D827A; or
(b) consists of SEQ ID NO: 27.

### Claim at position 30

-50. (canceled)

### Claim 51 (depends on 21)

The method of claim 21, wherein the error-prone adenoviral DNA polymerase is constitutively expressed in the engineered, non-naturally occurring metazoan cells.

### Claim 52 (depends on 21)

The method of claim 21, wherein a small molecule is added to the culture conditions to increase selection stringency, wherein the small molecule decreases the functionality of the protein necessary for the production of infectious DNA viral particles.

### Claim 53

(canceled)
